{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:04:08Z","timestamp":1772816648729,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N013638\/1"],"award-info":[{"award-number":["MR\/N013638\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N013638\/1"],"award-info":[{"award-number":["MR\/N013638\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N013638\/1"],"award-info":[{"award-number":["MR\/N013638\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","award":["A1256"],"award-info":[{"award-number":["A1256"]}],"id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","award":["A1256"],"award-info":[{"award-number":["A1256"]}],"id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the absence of a correlate(s) of protection against human tuberculosis and a validated animal model of the disease, tools to facilitate vaccine development must be identified. We present an optimised <jats:italic>ex vivo<\/jats:italic> mycobacterial growth inhibition assay (MGIA) to assess the ability of host cells within the lung to inhibit mycobacterial growth, including Bacille Calmette\u2013Gu\u00e9rin (BCG) and <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (MTB) Erdman. Growth of BCG was reduced by 0.39, 0.96 and 0.73 log<jats:sub>10<\/jats:sub> CFU following subcutaneous (s.c.) BCG, intranasal (i.n.) BCG, or BCG s.c. + mucosal boost, respectively, versus na\u00efve mice. Comparatively, a 0.49 (s.c.), 0.60 (i.n.) and 0.81 (s.c. + mucosal boost) log<jats:sub>10<\/jats:sub> reduction in MTB CFU was found. A BCG growth inhibitor, 2-thiophenecarboxylic acid hydrazide (TCH), was used to prevent quantification of residual BCG from i.n. immunisation and allow accurate MTB quantification. Using TCH, a further 0.58 log<jats:sub>10<\/jats:sub> reduction in MTB CFU was revealed in the i.n. group. In combination with existing methods, the <jats:italic>ex vivo<\/jats:italic> lung MGIA may represent an important tool for analysis of vaccine efficacy and the immune mechanisms associated with vaccination in the organ primarily affected by MTB disease.<\/jats:p>","DOI":"10.1038\/s41598-020-60223-y","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T11:07:31Z","timestamp":1582542451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Adaption of the ex vivo mycobacterial growth inhibition assay for use with murine lung cells"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0445-7473","authenticated-orcid":false,"given":"Hannah","family":"Painter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satria A.","family":"Prabowo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Cia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Stockdale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Willcocks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajko","family":"Reljic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-1006","authenticated-orcid":false,"given":"Helen A.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Zelmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"key":"60223_CR1","unstructured":"World Health Organization. Global Tuberculosis Report 2018. (2018)."},{"key":"60223_CR2","unstructured":"WHO. The End TB Strategy. (2015)."},{"key":"60223_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.g4643","volume":"349","author":"A Roy","year":"2014","unstructured":"Roy, A. et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: Systematic review and meta-analysis. BMJ 349, 1\u201311 (2014).","journal-title":"BMJ"},{"key":"60223_CR4","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/S0140-6736(95)92348-9","volume":"346","author":"PEM Fine","year":"1995","unstructured":"Fine, P. E. M. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346, 1339\u20131345 (1995).","journal-title":"Lancet"},{"key":"60223_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1714021","volume":"379","author":"E Nemes","year":"2018","unstructured":"Nemes, E. et al. Prevention of M. Tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N. Engl. J. Med. 379, 138\u2013149 (2018).","journal-title":"N. Engl. J. Med."},{"key":"60223_CR6","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","volume":"379","author":"O Van Der Meeren","year":"2018","unstructured":"Van Der Meeren, O. et al. Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis. N. Engl. J. Med. 379, 1621\u20131634 (2018).","journal-title":"N. Engl. J. Med."},{"key":"60223_CR7","first-page":"1","volume":"33","author":"SB Sable","year":"2020","unstructured":"Sable, S. B., Posey, J. E. & Scriba, T. J. Tuberculosis Vaccine Development: Progress in Clinical Evaluation. Clin. Microbiol. Rev. 33, 1\u201330 (2020).","journal-title":"Clin. Microbiol. Rev."},{"key":"60223_CR8","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1164\/rccm.201003-0334OC","volume":"182","author":"BMN Kagina","year":"2010","unstructured":"Kagina, B. M. N. et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Gu\u00e9rin vaccination of newborns. Am. J. Respir. Crit. Care Med. 182, 1073\u20131079 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"60223_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11290","volume":"7","author":"HA Fletcher","year":"2016","unstructured":"Fletcher, H. A. et al. T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nat. Commun. 7, 11290 (2016).","journal-title":"Nat. Commun."},{"key":"60223_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1365-2249.2012.04614.x","volume":"169","author":"F Abebe","year":"2012","unstructured":"Abebe, F. Is interferon-gamma the right marker for bacille Calmette-Gu\u00e9rin-induced immune protection? The missing link in our understanding of tuberculosis immunology. Clin. Exp. Immunol. 169, 213\u2013219 (2012).","journal-title":"Clin. Exp. Immunol."},{"key":"60223_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0136500","volume":"10","author":"M Henao-Tamayo","year":"2015","unstructured":"Henao-Tamayo, M. et al. The efficacy of the BCG vaccine against newly emerging clinical strains of mycobacterium tuberculosis. PLoS One 10, 1\u201315 (2015).","journal-title":"PLoS One"},{"key":"60223_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1365-2249.2006.03162.x","volume":"145","author":"F Abebe","year":"2006","unstructured":"Abebe, F. & Bjune, G. The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Gu\u00e9rin (BCG) vaccines: Is there a link? Clin. Exp. Immunol. 145, 389\u2013397 (2006).","journal-title":"Clin. Exp. Immunol."},{"key":"60223_CR13","doi-asserted-by":"publisher","first-page":"e0214088","DOI":"10.1371\/journal.pone.0214088","volume":"14","author":"S Borrell","year":"2019","unstructured":"Borrell, S. et al. Reference Set of Mycobacterium tuberculosis Clinical Strains: A tool for research and product development. PLoS One 14, e0214088 (2019).","journal-title":"PLoS One"},{"key":"60223_CR14","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1016\/j.vaccine.2016.07.058","volume":"34","author":"R Tanner","year":"2016","unstructured":"Tanner, R., O\u2019Shea, M. K., Fletcher, H. A. & McShane, H. In vitro mycobacterial growth inhibition assays: A tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy. Vaccine 34, 4656\u20134665 (2016).","journal-title":"Vaccine"},{"key":"60223_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1128\/CVI.00742-13","volume":"21","author":"K Kolibab","year":"2013","unstructured":"Kolibab, K., Yang, A., Parra, M., Derrick, S. C. & M., S. L. Time to Detection of Mycobacterium tuberculosis Using the MGIT 320 System Correlates with Colony Counting in Preclinical Testing of New Vaccines. Clin. Vaccine Immunol. 21, 453\u2013455 (2013).","journal-title":"Clin. Vaccine Immunol."},{"key":"60223_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.14573\/altex.1607281","volume":"34","author":"R Tanner","year":"2017","unstructured":"Tanner, R. & Mcshane, H. Replacing, reducing & refining the use of animals in tuberculosis vaccine research. ALTEX 34, 157\u2013166 (2017).","journal-title":"ALTEX"},{"key":"60223_CR17","first-page":"198","volume":"54","author":"N Burden","year":"2015","unstructured":"Burden, N., Chapman, K., Sewell, F. & Robinson, V. Pioneering better science through the 3Rs: an introduction to the national centre for the replacement, refinement, and reduction of animals in research (NC3Rs). J. Am. Assoc. Lab. Anim. Sci. 54, 198\u2013208 (2015).","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"60223_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02116-1","volume":"7","author":"C Jensen","year":"2017","unstructured":"Jensen, C., Lindebo Holm, L., Svensson, E., Aagaard, C. & Ruhwald, M. Optimisation of a murine splenocyte mycobacterial growth inhibition assay using virulent Mycobacterium tuberculosis. Sci. Rep. 7, 2830 (2017).","journal-title":"Sci. Rep."},{"key":"60223_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1751-4","volume":"16","author":"A Zelmer","year":"2016","unstructured":"Zelmer, A., Tanner, R., Stylianou, E., Damelang, T. & Morris, S. A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG- mediated protection in a murine model of tuberculosis. BMC Infect. Dis. 16, 412 (2016).","journal-title":"BMC Infect. Dis."},{"key":"60223_CR20","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1128\/CVI.00067-09","volume":"16","author":"M Parra","year":"2009","unstructured":"Parra, M. et al. Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis. Clin. Vaccine Immunol. 16, 1025\u20131032 (2009).","journal-title":"Clin. Vaccine Immunol."},{"key":"60223_CR21","doi-asserted-by":"publisher","first-page":"e00142","DOI":"10.1128\/CVI.00142-17","volume":"24","author":"MJ Brennan","year":"2017","unstructured":"Brennan, M. J. et al. The Cross-species Mycobacterial Growth Inhibition Assay (MGIA) Project 2010-2014. Clin. Vaccine Immunol. 24, e00142\u201317 (2017).","journal-title":"Clin. Vaccine Immunol."},{"key":"60223_CR22","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1086\/344359","volume":"186","author":"DF Hoft","year":"2002","unstructured":"Hoft, D. F. et al. Investigation of the Relationships between Immune\u2010Mediated Inhibition of Mycobacterial Growth and Other Potential Surrogate Markers of Protective Mycobacterium tuberculosis Immunity. J. Infect. Dis. 186, 1448\u20131457 (2002).","journal-title":"J. Infect. Dis."},{"key":"60223_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.tube.2013.04.007","volume":"93","author":"L Marsay","year":"2013","unstructured":"Marsay, L. et al. Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M. tb). Tuberculosis 93, 551\u2013557 (2013).","journal-title":"Tuberculosis"},{"key":"60223_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3389\/fimmu.2018.00346","volume":"9","author":"A Copland","year":"2018","unstructured":"Copland, A. et al. Mucosal delivery of fusion proteins with Bacillus subtilis spores enhances protection against tuberculosis by Bacillus Calmette-Gu\u00e9rin. Front. Immunol. 9, 346 (2018).","journal-title":"Front. Immunol."},{"key":"60223_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/trstmh\/tru206","volume":"109","author":"ZM Thomas","year":"2015","unstructured":"Thomas, Z. M. & Mcshane, H. Aerosol immunisation for TB: matching route of vaccination to route of infection. Trans R Soc Trop Med Hyg 109, 175\u2013181 (2015).","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"60223_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17765-5","volume":"8","author":"MK O\u2019Shea","year":"2018","unstructured":"O\u2019Shea, M. K. et al. Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection. Sci. Rep. 8, 1\u201313 (2018).","journal-title":"Sci. Rep."},{"key":"60223_CR27","doi-asserted-by":"publisher","unstructured":"Zelmer, A. et al. Ex vivo mycobacterial growth inhibition assay (MGIA) for tuberculosis vaccine testing - a protocol for mouse splenocytes. bioRxiv 1\u201310. https:\/\/doi.org\/10.1101\/020560 (2015).","DOI":"10.1101\/020560"},{"key":"60223_CR28","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1128\/JCM.40.7.2339-2345.2002","volume":"40","author":"LM Parsons","year":"2002","unstructured":"Parsons, L. M. et al. Rapid and Simple Approach for Identification of Mycobacterium tuberculosis Complex Isolates by PCR-Based Genomic Deletion Analysis. J. Clin. Microbiol. 40, 2339\u20132345 (2002).","journal-title":"J. Clin. Microbiol."},{"key":"60223_CR29","doi-asserted-by":"publisher","first-page":"e22718","DOI":"10.1371\/journal.pone.0022718","volume":"6","author":"SB Sable","year":"2011","unstructured":"Sable, S. B. et al. Cellular immune responses to nine Mycobacterium tuberculosis vaccine candidates following intranasal vaccination. PLoS One 6, e22718 (2011).","journal-title":"PLoS One"},{"key":"60223_CR30","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1128\/CVI.00394-14","volume":"21","author":"SC Derrick","year":"2014","unstructured":"Derrick, S. C., Kolibab, K., Yang, A. & Morris, S. L. Intranasal administration of Mycobacterium bovis BCG induces superior protection against aerosol infection with Mycobacterium tuberculosis in mice. Clin. Vaccine Immunol. 21, 1443\u20131451 (2014).","journal-title":"Clin. Vaccine Immunol."},{"key":"60223_CR31","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3389\/fimmu.2018.01708","volume":"9","author":"J Radloff","year":"2018","unstructured":"Radloff, J. et al. Mycobacterium Growth Inhibition Assay of Human Alveolar Macrophages as a Correlate of Immune Protection Following Mycobacterium bovis Bacille Calmette-Gu\u00e9rin Vaccination. Front. Immunol. 9, 1708 (2018).","journal-title":"Front. Immunol."},{"key":"60223_CR32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/0041-3879(86)90018-8","volume":"67","author":"J Steele","year":"1986","unstructured":"Steele, J. et al. Inhibition of virulent Mycobacterium tuberculosis by murine peritoneal macrophagesand human alveolar lavage cells: The effects of lymphokines and recombinant gamma interferon. Tubercle 67, 289\u2013294 (1986).","journal-title":"Tubercle"},{"key":"60223_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2019.01.006","volume":"469","author":"R Tanner","year":"2019","unstructured":"Tanner, R. et al. Optimisation, harmonisation and standardisation of the direct mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells. J. Immunol. Methods 469, 1\u201310 (2019).","journal-title":"J. Immunol. Methods"},{"key":"60223_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.mimet.2016.09.010","volume":"131","author":"AL Yang","year":"2016","unstructured":"Yang, A. L., Schmidt, T. E., Stibitz, S. & Morris, S. L. A simplified mycobacterial growth inhibition assay (MGIA) using direct infection of mouse splenocytes and the MGIT system. J. Microbiol. Methods 131, 7\u20139 (2016).","journal-title":"J. Microbiol. Methods"},{"key":"60223_CR35","unstructured":"Kent, P. T., K. G. Public health mycobacteriology. A guide for the level III laboratory. (1985)."},{"key":"60223_CR36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1128\/JCM.38.1.152-157.2000","volume":"38","author":"S Niemann","year":"2000","unstructured":"Niemann, S., Richter, E. & R\u00fcsch-Gerdes, S. Differentiation among members of the Mycobacterium tuberculosis complex by molecular and biochemical features: Evidence for two pyrazinamide- susceptible subtypes of M. bovis. J. Clin. Microbiol. 38, 152\u2013157 (2000).","journal-title":"J. Clin. Microbiol."},{"key":"60223_CR37","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jinf.2005.12.017","volume":"53","author":"PK Giri","year":"2006","unstructured":"Giri, P. K., Verma, I. & Khuller, G. K. Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. J. Infect. 53, 350\u2013356 (2006).","journal-title":"J. Infect."},{"key":"60223_CR38","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1128\/IAI.72.1.238-246.2004","volume":"72","author":"L Chen","year":"2004","unstructured":"Chen, L. et al. Single Intranasal Mucosal Mycobacterium bovis BCG Vaccination Confers Improved Protection Compared to Subcutaneous Vaccination against Pulmonary Tuberculosis. Infect Immun 72, 238\u2013246 (2004).","journal-title":"Infect Immun"},{"key":"60223_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/ani4010035","volume":"4","author":"C Kilkenny","year":"2013","unstructured":"Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: The arrive guidelines for reporting animal research. Animals 4, 35\u201344 (2013).","journal-title":"Animals"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60223-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60223-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60223-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:54:16Z","timestamp":1670313256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60223-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["60223"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-60223-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]},"assertion":[{"value":"2 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3311"}}